Abstract 421P
Background
LEN is a multikinase inhibitor of VEGFRs 1–3, FGFRs 1–4, PDGFRα, RET, and KIT that resulted in significantly prolonged progression-free survival (PFS) compared with PBO in pts with RR-DTC in a phase III study (SELECT). However, SELECT did not include pts from China. As data in Chinese pts are required for approval of LEN for RR-DTC in China, we conducted a phase III study of RR-DTC treated with LEN vs PBO in Chinese pts.
Methods
This randomized, multicenter, double-blind, PBO-controlled study enrolled pts aged ≥18 years with RR-DTC and confirmed disease progression in the past 12 months. Pts were stratified by tumor subtype (papillary or follicular), number of prior VEGF/VEGFR-targeted therapies (0 or 1), and age (≤65 years or >65 years). LEN starting dose was 24 mg/day. The primary endpoint was PFS by independent imaging review based on RECIST v1.1. A one-sided significance level of 0.01 was utilized in the planned interim analysis. Secondary endpoints included overall response rate (ORR), overall survival, and safety.
Results
Overall, 151 Chinese pts (median age, 60 years; 52% men) were randomized 2:1 (LEN, n = 103; PBO, n = 48). At the recommendation of the Independent Data Monitoring Committee at the time of the interim analysis, the randomization phase of this study was stopped early because of positive efficacy and we conducted the primary analysis using the interim analysis cutoff date. In the LEN and PBO arms, the median durations of follow-up were 14.8 and 15.6 months, respectively. PFS was significantly improved with LEN (median 23.9 months; 95% CI 12.9–not estimable) vs PBO (median 3.7 months; 95% CI 1.9–5.6) (hazard ratio = 0.16, 95% CI 0.10–0.26; P < 0.0001 [logrank]). ORR was 69.9% with LEN and 0% with PBO. The most common treatment-related grade ≥3 adverse events (LEN, PBO) were hypertension (62.1%, 4.2%), proteinuria (23.3%, 0%), and palmar-plantar erythrodysesthesia syndrome (9.7%, 0%).
Conclusions
LEN significantly prolonged PFS compared with PBO in Chinese pts with RR-DTC, similar to the global phase III SELECT results. There were no new or unexpected toxicities with LEN in Chinese pts with RR-DTC.
Clinical trial identification
NCT02966093.
Editorial acknowledgement
Medical writing was provided by Oxford PharmaGenesis Inc., Newtown, PA, USA, and was funded by Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Eisai Co., Ltd., Tokyo, Japan, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA.
Funding
Eisai Inc. and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Disclosure
T. Kubota, T. Suzuki, H. Ikezawa: Full/Part-time employment: Eisai Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
34P - Clinical significance of neoadjuvant dose-dense chemotherapy for II and III stage breast cancer: A meta-analysis of published studies
Presenter: Meng chen Liu
Session: e-Poster Display Session
35P - Pathological response to weekly nabpaclitaxel and carboplatin followed by anthracycline regimen in triple negative breast cancer
Presenter: Goteti Sharat Chandra
Session: e-Poster Display Session
36P - Survival in patients with contralateral breast cancer
Presenter: Sergey Kamishov
Session: e-Poster Display Session
37P - Correlation between haematological toxicity with quality of life in breast cancer patients after first-cycle chemotherapy
Presenter: felix Wijovi
Session: e-Poster Display Session
38P - Evaluation of the prognostic value of innate immunity-related biomarkers in early breast cancer (BC)
Presenter: Veronica Martini
Session: e-Poster Display Session
39P - CSF-1R inhibitor (C019199) enhances antitumor effect in combination with anti-PD-1 therapy on murine breast cancer models
Presenter: Jiani Zheng
Session: e-Poster Display Session
40P - Molecular subtypes and imaging phenotypes of breast cancer: MRI
Presenter: Yulduz Khatamovna
Session: e-Poster Display Session
41P - Mir-223 overexpression is associated with increased expression of EGFR and worse prognosis in Indonesian TNBC patients
Presenter: Ibnu Purwanto
Session: e-Poster Display Session
42P - Impact of germline mutations on breast cancer prognosis in Kazakh population
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
50P - Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
Presenter: Yijia Hua
Session: e-Poster Display Session